Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
Österborg A, Wierda WG, Mayer J, Hess G, Hillmen P, Schetelig J, Schuh A, Smolej L, Beck C, Dreyfus B, Hellman A, Kozlowski P, Pfreundschuh M, Rizzi R, Spacek M, Phillips JL, Gupta IV, Williams V, Jewell RC, Nebot N, Lisby S, Dyer MJ. Österborg A, et al. Among authors: jewell rc. Br J Haematol. 2015 Jul;170(1):40-9. doi: 10.1111/bjh.13380. Epub 2015 Mar 30. Br J Haematol. 2015. PMID: 25825041 Free article. Clinical Trial.
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma.
Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Strange C, Windfeld K, Viardot A; 409 Study Investigators. Czuczman MS, et al. Among authors: jewell rc. Br J Haematol. 2012 May;157(4):438-45. doi: 10.1111/j.1365-2141.2012.09086.x. Epub 2012 Mar 13. Br J Haematol. 2012. PMID: 22409295 Free article. Clinical Trial.
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmen P, Trnêný M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG; Hx-CD20-406 Study Investigators. Österborg A, et al. Among authors: jewell rc. Haematologica. 2015 Aug;100(8):e311-4. doi: 10.3324/haematol.2014.121459. Epub 2015 Mar 13. Haematologica. 2015. PMID: 25769539 Free PMC article. No abstract available.
Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy.
Jewell RC, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Smolej L, Mayer J, Hess G, Hernandez-Ilizaliturri FJ, Padmanabhan-Iyer S, Fang L, Goldstein N, Gorczyca M, Gupta I, Lisby S, Wierda WG; Hx-CD20-407 Study Investigators. Jewell RC, et al. Leuk Lymphoma. 2017 Feb;58(2):348-356. doi: 10.1080/10428194.2016.1195497. Epub 2016 Jul 7. Leuk Lymphoma. 2017. PMID: 27389174 Free PMC article. Clinical Trial.
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.
Coiffier B, Radford J, Bosly A, Martinelli G, Verhoef G, Barca G, Davies A, Decaudin D, Gallop-Evans E, Padmanabhan-Iyer S, Van Eygen K, Wu KL, Gupta IV, Lin TS, Goldstein N, Jewell RC, Winter P, Lisby S; 415 study investigators. Coiffier B, et al. Among authors: jewell rc. Br J Haematol. 2013 Nov;163(3):334-42. doi: 10.1111/bjh.12537. Epub 2013 Aug 23. Br J Haematol. 2013. PMID: 24032456 Free article. Clinical Trial.
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.
Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, DiRienzo CG, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Schultz M, Russell CA, Hagenbeek A; 405 Study Investigators. Czuczman MS, et al. Among authors: jewell rc. Blood. 2012 Apr 19;119(16):3698-704. doi: 10.1182/blood-2011-09-378323. Epub 2012 Mar 2. Blood. 2012. PMID: 22389254 Free article. Clinical Trial.
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Furman RR, et al. Among authors: jewell rc. Lancet Haematol. 2017 Jan;4(1):e24-e34. doi: 10.1016/S2352-3026(16)30166-1. Epub 2016 Dec 1. Lancet Haematol. 2017. PMID: 27914971 Free PMC article. Clinical Trial.
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
Richardson PG, Lee HC, Abdallah AO, Cohen AD, Kapoor P, Voorhees PM, Hoos A, Wang K, Baron J, Piontek T, Byrne J, Richmond S, Jewell RC, Opalinska J, Gupta I, Lonial S. Richardson PG, et al. Among authors: jewell rc. Blood Cancer J. 2020 Oct 23;10(10):106. doi: 10.1038/s41408-020-00369-0. Blood Cancer J. 2020. PMID: 33097687 Free PMC article. Clinical Trial.
50 results